Cargando…

Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study

BACKGROUND: Current literature still lacks studies evaluating the effectiveness and safety of switching from Infliximab originator to SB2 biosimilar in Inflammatory Bowel Diseases (IBDs). We aimed to verify the ability of SB2 to maintain the clinical and biochemical response induced by originator af...

Descripción completa

Detalles Bibliográficos
Autores principales:	Massimi, Davide, Barberio, Brigida, Bertani, Lorenzo, Costa, Francesco, Ferronato, Antonio, Facchin, Sonia, Cardin, Romilda, Cingolani, Linda, Casadei, Cesare, D’Incà, Renata, Zingone, Fabiana, Savarino, Edoardo Vincenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239954/ https://www.ncbi.nlm.nih.gov/pubmed/34249147 http://dx.doi.org/10.1177/17562848211023384

Ejemplares similares

Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator
por: Cingolani, Linda, et al.
Publicado: (2021)

Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study
por: Barberio, Brigida, et al.
Publicado: (2020)

Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients
por: Facchin, Sonia, et al.
Publicado: (2021)

A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study
por: Barberio, Brigida, et al.
Publicado: (2021)

Faecal microbiota transplantation in Clostridioides difficile infection: real-life experience from an academic Italian hospital
por: Barberio, Brigida, et al.
Publicado: (2020)

Serum Levels of PCSK9 Are Increased in Patients With Active Ulcerative Colitis Representing a Potential Biomarker of Disease Activity: A Cross-sectional Study
por: Marinelli, Carla, et al.
Publicado: (2022)

A Survey on Nutritional Knowledge in Coeliac Disease Compared to Inflammatory Bowel Diseases Patients and Healthy Subjects
por: Marsilio, Ilaria, et al.
Publicado: (2020)

The Adherence to Infusible Biologic Therapies in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic: Is It Really a Problem?
por: Barberio, Brigida, et al.
Publicado: (2021)

Perception of the COVID-19 Pandemic Among Patients With Inflammatory Bowel Disease in the Time of Telemedicine: Cross-Sectional Questionnaire Study
por: Zingone, Fabiana, et al.
Publicado: (2020)

Good efficacy and safety of vedolizumab in Crohn’s disease and ulcerative colitis in a real-world scenario
por: Zingone, Fabiana, et al.
Publicado: (2020)

Medical and gastroenterological education during the COVID-19 outbreak
por: Barberio, Brigida, et al.
Publicado: (2020)

Factors Influencing Disability and Quality of Life during Treatment: A Cross-Sectional Study on IBD Patients
por: Marinelli, Carla, et al.
Publicado: (2019)

AF.48 COMPARATIVE ASSESSMENT OF ADALIMUMAB TROUGH LEVELS BETWEEN POINT-OF-CARE TESTING AND CURRENT STANDARD OF CARE (ENZYME LINKED IMMUNOSORBENT ASSAY) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Marsilio, I., et al.
Publicado: (2021)

Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars
por: Ebbers, Hans C., et al.
Publicado: (2020)

A specific microbiota signature is associated to various degrees of ulcerative colitis as assessed by a machine learning approach
por: Barberio, Brigida, et al.
Publicado: (2022)

Reorganization of the functional gastrointestinal disorders unit during the SARS-CoV-2 outbreak - Practical Recommendations
por: Ghisa, Matteo, et al.
Publicado: (2020)

No need of transforming gastroenterology units to covid units at the time of SARS-COV2 infection - a single-center analysis from northern italy
por: Zingone, Fabiana, et al.
Publicado: (2020)

Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab)
por: Hong, Juyong, et al.
Publicado: (2016)

Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation
por: Barberio, Brigida, et al.
Publicado: (2022)

Lack of complications in patients with eosinophilic gastrointestinal diseases during SARS-CoV-2 outbreak
por: Savarino, Edoardo, et al.
Publicado: (2020)

Efficacy of teduglutide in a patient with Crohn’s disease and short bowel syndrome on enteral nutrition: let’s start to think out of the box
por: Barberio, Brigida, et al.
Publicado: (2019)

The Lyon Consensus: Does It Differ From the Previous Ones?
por: Ghisa, Matteo, et al.
Publicado: (2020)

Azathioprine monotherapy withdrawal in inflammatory bowel diseases: A retrospective mono-centric study
por: Crepaldi, Martina, et al.
Publicado: (2023)

Fecal microbiota transplantation for norovirus infection: a clinical and microbiological success
por: Barberio, Brigida, et al.
Publicado: (2020)

Real-world evidence of the use of the infliximab biosimilar SB2: data from the PERFUSE study
por: Fautrel, Bruno, et al.
Publicado: (2023)

Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data
por: Marabotto, Elisa, et al.
Publicado: (2020)

Efficacy and safety of oral beclomethasone dipropionate and budesonide MMX versus 5-aminosalicylates or placebo in ulcerative colitis: a systematic review and meta-analysis
por: Barberio, Brigida, et al.
Publicado: (2023)

Sleep disturbance in Inflammatory Bowel Disease: prevalence and risk factors – A cross-sectional study
por: Marinelli, C., et al.
Publicado: (2020)

PERFUSE: Non-Interventional Cohort Study of Patients Receiving Infliximab Biosimilar SB2: Results in Pediatric Patients
por: Martinez-Vinson, Christine, et al.
Publicado: (2022)

Clinical and Psychological Impact of COVID-19 Infection in Adult Patients with Eosinophilic Gastrointestinal Disorders during the SARS-CoV-2 Outbreak
por: Savarino, Edoardo Vincenzo, et al.
Publicado: (2020)

Hospitalisation for Drug Infusion Did Not Increase Levels of Anxiety and the Risk of Disease Relapse in Patients with Inflammatory Bowel Disease during COVID-19 Outbreak
por: Bertani, Lorenzo, et al.
Publicado: (2021)

Infusion reaction to infliximab biosimilar after transitioning from infliximab
por: Kashlan, Reem, et al.
Publicado: (2020)

Viral screening before initiation of biologics in patients with inflammatory bowel disease during the COVID-19 outbreak
por: Zingone, Fabiana, et al.
Publicado: (2020)

The Risk of Malignancies in Celiac Disease—A Literature Review
por: Pelizzaro, Filippo, et al.
Publicado: (2021)

Biosimilar infliximab use in paediatric IBD
por: Richmond, Lisa, et al.
Publicado: (2018)

Immunolocalization of leptin and leptin receptor in colorectal mucosa of ulcerative colitis, Crohn’s disease and control subjects with no inflammatory bowel disease
por: Merigo, Flavia, et al.
Publicado: (2020)

Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events
por: Subedi, Smriti, et al.
Publicado: (2019)

Reply to comment: Asymptomatic screening for SARS COV-2 prior to commencement of biologic therapies in patients with inflammatory bowel disease - a potentially harmful practice
por: Zingone, Fabiana, et al.
Publicado: (2020)

Reply to comment: Screening for active COVID-19 infection prior to biologic therapy in IBD patients: primum non nŏcēre
por: Zingone, Fabiana, et al.
Publicado: (2020)

Sarcopenia, severe anxiety and increased C-reactive protein are associated with severe fatigue in patients with inflammatory bowel diseases
por: Tasson, Laura, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mim7cm991ndslqmevrvrufa34p